The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

These biomarkers developed through analysis of DNA methylation appear to be the first ones able to predict response to ...

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Fintel reports that on July 9, 2025, Piper Sandler initiated coverage of Inovio Pharmaceuticals (NasdaqCM:INO) with a ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

The country's premier medical institution said that its studies have found no connection between Covid jabs and sudden deaths ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The Genomics business benefited from 20% volume growth in oncology tests (legacy Tempus clinical testing) and higher average revenue per test, driven by increased Medicare reimbur ...

When the Covid-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people - but in the background there was ...

The Global Bioinformatics Market is expected to grow at a rate of 13-14% by 2029. The rising government initiatives and funding for genomics research, increasing applications of bioinformatics in drug ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...